Detailed price information for Vera Therapeutics Inc Cl A (VERA-Q) from The Globe and Mail including charting and trades.

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) today reported financial results for the second quarter 2025 and provided a business ...

Present results of the TACTIVE-N trial, a Phase 2 clinical trial of neoadjuvant vepdegestrant, in a mini oral session at European Society for Medical Oncology 2025 Congress (ClinicalTrials.gov ...

Key Points Non-GAAP EPS was ($0.13), missing the consensus estimate by $0.02 (non-GAAP), due to higher pre-commercialization spending. Research and development expenses fell 48.2% compared to Q2 2024, ...

Operating expenses decreased sharply compared to Q2 2024, supporting a cash runway into the second quarter of 2026. - Dose expansion enrollment was completed for the lead product in its main clinical ...

Key Points OJEMDA net product revenue surged 310% year over year to $33.6 million in Q2 2025, driving total quarterly revenue (GAAP) to $33.9 million but narrowly missed consensus expectations for ...

Balance Sheet: At June 30, 2025, Cumberland had approximately $68 million in total assets, including $16 million in cash and cash equivalents. Liabilities totaled $40 million, including $5 million on ...

Fox holds very attractive sports rights, and Fox News is the long-running leader in cable news viewership, giving Fox pricing power that helps it offset the decline in pay TV subscribers and buck the ...

Accounting firms today are at a crossroads. While client demands, regulatory pressures, and workloads have evolved dramatically, the tools used to handle ...

Good morning, and welcome to the Icahn Enterprises L.P. Second Quarter 2025 Earnings Call with Andrew Teno, President and CEO and and Ted Papapostolou, Chief Financial Officer; and Robert Flint, Chief ...

RESEARCH TRIANGLE PARK, N.C., Aug. 04, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today reported ...

Q2 2025 Earnings Call Transcript August 1, 2025 Fulgent Genetics, Inc. misses on earnings expectations. Reported EPS is $-0.62065 EPS, expectations were $-0.23. Operator: Greetings, and welcome to the ...